DE69902396D1 - Stabilisierte flüssige arzneizubereitungen enthaltend botulinum toxin - Google Patents
Stabilisierte flüssige arzneizubereitungen enthaltend botulinum toxinInfo
- Publication number
- DE69902396D1 DE69902396D1 DE69902396T DE69902396T DE69902396D1 DE 69902396 D1 DE69902396 D1 DE 69902396D1 DE 69902396 T DE69902396 T DE 69902396T DE 69902396 T DE69902396 T DE 69902396T DE 69902396 D1 DE69902396 D1 DE 69902396D1
- Authority
- DE
- Germany
- Prior art keywords
- botulinum toxin
- preparations containing
- liquid drug
- stabilized liquid
- drug preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9987098P | 1998-09-11 | 1998-09-11 | |
US99870P | 1998-09-11 | ||
PCT/US1999/020912 WO2000015245A2 (en) | 1998-09-11 | 1999-09-09 | Stable liquid formulations of botulinum toxin |
Publications (3)
Publication Number | Publication Date |
---|---|
DE69902396D1 true DE69902396D1 (de) | 2002-09-05 |
DE69902396T2 DE69902396T2 (de) | 2003-03-20 |
DE69902396T3 DE69902396T3 (de) | 2010-09-30 |
Family
ID=22277018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69902396T Expired - Lifetime DE69902396T3 (de) | 1998-09-11 | 1999-09-09 | Stabilisierte flüssige arzneizubereitungen enthaltend botulinum toxin |
Country Status (41)
Country | Link |
---|---|
US (2) | US7211261B1 (de) |
EP (1) | EP1112082B2 (de) |
JP (4) | JP4557426B2 (de) |
KR (1) | KR100699756B1 (de) |
CN (1) | CN100438905C (de) |
AP (1) | AP1591A (de) |
AR (1) | AR022671A1 (de) |
AT (1) | ATE221386T1 (de) |
AU (1) | AU755556C (de) |
BG (1) | BG65555B1 (de) |
BR (1) | BR9913585A (de) |
CA (1) | CA2342243C (de) |
CO (1) | CO5170497A1 (de) |
CU (1) | CU23251A3 (de) |
DE (1) | DE69902396T3 (de) |
DK (1) | DK1112082T4 (de) |
EA (1) | EA003367B1 (de) |
EE (1) | EE200100140A (de) |
ES (1) | ES2181473T5 (de) |
GE (1) | GEP20032946B (de) |
HK (1) | HK1040927A1 (de) |
HR (1) | HRP20010259B1 (de) |
HU (1) | HUP0103638A3 (de) |
ID (1) | ID28824A (de) |
IL (2) | IL141564A0 (de) |
IS (1) | IS2381B (de) |
LT (1) | LT4959B (de) |
LV (1) | LV12684B (de) |
NO (1) | NO328898B1 (de) |
NZ (1) | NZ509349A (de) |
PL (1) | PL200926B1 (de) |
PT (1) | PT1112082E (de) |
RS (1) | RS50344B (de) |
SA (1) | SA99200566B1 (de) |
SI (2) | SI20566B (de) |
SK (1) | SK286919B6 (de) |
TR (1) | TR200100728T2 (de) |
TW (1) | TW574036B (de) |
UA (1) | UA72477C2 (de) |
WO (1) | WO2000015245A2 (de) |
ZA (1) | ZA200101709B (de) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3066079B2 (ja) * | 1994-05-09 | 2000-07-17 | ビンダー,ウィリアム,ジェイ. | 頭痛を低減する方法 |
TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
US20120238504A1 (en) * | 1998-09-11 | 2012-09-20 | Solstice Neurosciences, Llc | Stable Formulations of Botulinum Toxin in Hydrogels |
DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
EP1586329A1 (de) * | 2000-02-08 | 2005-10-19 | Allergan, Inc. | Pharmazeutische Zusammensetzungen mit botulinum Toxin |
US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US6821520B2 (en) | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
ITUD20010002A1 (it) | 2001-01-05 | 2002-07-05 | Univ Degli Studi Udine | Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo |
CA2369810C (en) * | 2002-01-30 | 2007-08-07 | 1474791 Ontario Limited | Method of treating pain |
US7140371B2 (en) | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
EP1491205A4 (de) * | 2002-03-29 | 2007-04-25 | Chemo Sero Therapeut Res Inst | Mittel zur behandlung von hypermyotonie |
US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
CA2854831C (en) | 2002-11-21 | 2016-08-30 | Ira Sanders | Treatment of mammalian reaction to ige interactions |
MXPA05006690A (es) * | 2002-12-20 | 2006-02-17 | Botulinum Toxin Res Ass Inc | Composiciones farmaceuticas de toxina botulinica mejoradas. |
US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
MXPA05009425A (es) * | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica. |
WO2004078200A1 (en) * | 2003-03-06 | 2004-09-16 | Botulinum Toxin Research Associates, Inc. | Selection of patients with increased responsiveness to botulinum toxin |
US6838434B2 (en) * | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
US8617572B2 (en) | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8609113B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8609112B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
AU2005251676B2 (en) | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
PT2656859E (pt) | 2004-03-03 | 2016-02-24 | Revance Therapeutics Inc | Aplicação tópica e administração transdérmica de toxinas botulínicas |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
KR100852822B1 (ko) | 2004-07-26 | 2008-08-18 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 신경독소를 포함하는 치료 조성물 |
US7179474B2 (en) | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
US7429386B2 (en) | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
WO2006073410A1 (en) * | 2005-01-03 | 2006-07-13 | Botulinum Toxin Research Associates, Inc. | Compositions, methods and devices for preparing less painful botulinum toxin formulations |
US9180081B2 (en) | 2005-03-03 | 2015-11-10 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7419675B2 (en) | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
DE102006019447A1 (de) * | 2006-04-24 | 2007-10-25 | Dressler, Dirk, Dr. | Markierung von Botulinum Toxin |
AR061669A1 (es) | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
JP2010529000A (ja) * | 2007-06-01 | 2010-08-26 | メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー | ボツリヌス毒素の神経毒成分をベースにした温度に安定な筋弛緩薬の提供方法 |
EP2048156A1 (de) * | 2007-10-12 | 2009-04-15 | Merz Pharma GmbH & Co.KGaA | Prozess zur Bereitstellung eines temperaturstabilen Muskelrelaxans auf der Basis der neurotoxischen Komponente von Botulintoxin |
US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
US20170361130A9 (en) * | 2008-05-23 | 2017-12-21 | Pankaj Modi | Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation |
WO2010016901A1 (en) * | 2008-08-05 | 2010-02-11 | Solstice Neurosciences, Inc. | Compositions of activated botulinum holotoxin type b (150 kd) |
EP2315598A1 (de) * | 2008-08-05 | 2011-05-04 | Solstice Neurosciences, Inc. | Zusammensetzungen aus aktiviertem botulintoxin vom typ b |
US20100112006A1 (en) * | 2008-11-03 | 2010-05-06 | Solstice Neurosciences, Inc. | Compositions of activated botulinum holotoxin type B (150 kD) |
WO2010051039A1 (en) * | 2008-11-03 | 2010-05-06 | Solstice Neurosciences, Inc. | Compositions of activated botulinum toxin type b |
US20100124559A1 (en) * | 2008-11-20 | 2010-05-20 | Allergan, Inc. | Early Treatment and Prevention of Increased Muscle Tonicity |
EP2364168A1 (de) | 2008-12-04 | 2011-09-14 | Botulinum Toxin Research Associates, Inc. | Verlängerte botulinustoxin-formulierung zur anwendung bei menschen oder säugetieren |
BRPI0923731B1 (pt) | 2008-12-31 | 2024-02-06 | Revance Therapeutics, Inc | Composições para uso em um método não-terapêutico de administração de toxina botulínica, seus usos e método de preparação |
EP2248518B1 (de) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulierung zur Stabilisierung von Proteinen, Peptiden und deren Mischungen. |
CN102869373B (zh) | 2009-06-25 | 2017-05-10 | 雷文斯治疗公司 | 不含白蛋白的肉毒杆菌毒素制剂 |
IN2012DN00733A (de) | 2009-07-02 | 2015-06-19 | Merz Pharma Gmbh & Co Kgaa | |
BR112012009227A2 (pt) | 2009-10-21 | 2016-08-23 | Revance Therapeutics Inc | métodos e sistemas para purificar neurotoxina botulínica não complexada |
AU2012209274A1 (en) * | 2011-01-24 | 2013-09-12 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
RU2646110C2 (ru) | 2011-11-09 | 2018-03-01 | Мерц Фарма Гмбх Унд Ко. Кгаа | Нейротоксины, проявляющие укороченную биологическую активность |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
MX370929B (es) | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
RU2535115C1 (ru) * | 2013-05-15 | 2014-12-10 | Бости Трейдинг Лтд | Фармацевтический состав, содержащий нейротоксин ботулина |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
WO2016036618A1 (en) * | 2014-09-02 | 2016-03-10 | American Silver, Llc | Botulinum toxin and colloidal silver particles |
AU2015371726B2 (en) * | 2014-12-23 | 2020-10-22 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin prefilled container |
SG11201706247VA (en) | 2015-02-03 | 2017-08-30 | Merz Pharma Gmbh & Co Kgaa | Botulinum toxin prefilled container |
JP7053498B2 (ja) * | 2016-05-27 | 2022-04-12 | ガルデルマ・ホールディング・エスアー | トリプトファンまたはチロシンで安定化された液体神経毒素製剤 |
WO2018038301A1 (en) * | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
TW202247855A (zh) | 2016-09-13 | 2022-12-16 | 美商愛力根公司 | 非蛋白梭菌毒素組成物 |
CN110198703A (zh) | 2016-11-21 | 2019-09-03 | 艾里奥治疗公司 | 大试剂的透皮递送 |
KR101744900B1 (ko) * | 2017-01-20 | 2017-06-08 | 주식회사 대웅 | 보툴리눔 독소를 포함하는 안정한 액상 조성물 |
KR20200006587A (ko) * | 2017-05-18 | 2020-01-20 | 레반스 테라퓨틱스, 아이엔씨. | 경부 근긴장이상증의 치료 방법 |
KR102063475B1 (ko) | 2018-02-22 | 2020-01-09 | 주식회사 에이비바이오 | 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법 |
WO2020074419A1 (en) | 2018-10-08 | 2020-04-16 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxin prefilled vial |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3522247A (en) * | 1967-11-07 | 1970-07-28 | Pfizer & Co C | 2-amino-6,7-disubstituted-4h-1,3-benzothiazine-4-ones as bronchodilators |
US4932936A (en) | 1988-01-29 | 1990-06-12 | Regents Of The University Of Minnesota | Method and device for pharmacological control of spasticity |
US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
US5919665A (en) * | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
US5183462A (en) * | 1990-08-21 | 1993-02-02 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
AU4646393A (en) * | 1992-06-23 | 1994-01-24 | Interactive Biologics Associates | Pharmaceutical composition containing botulinum b complex |
JPH06192118A (ja) * | 1992-09-28 | 1994-07-12 | Wisconsin Alumni Res Found | ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法 |
AU683275B2 (en) | 1993-06-10 | 1997-11-06 | Allergan, Inc. | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
EP0702561B1 (de) | 1993-06-10 | 2002-01-09 | Allergan, Inc. | Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e |
GB9315306D0 (en) | 1993-07-23 | 1993-09-08 | Smithkline Beecham Corp | Methods |
US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
DE69434610T2 (de) | 1993-12-28 | 2008-11-27 | Allergan, Inc., Irvine | Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
JP3066079B2 (ja) | 1994-05-09 | 2000-07-17 | ビンダー,ウィリアム,ジェイ. | 頭痛を低減する方法 |
AU2907695A (en) * | 1994-08-08 | 1996-03-07 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
US5562899A (en) | 1995-02-28 | 1996-10-08 | Gerber; Allen | Medical prevention of lacerations to the vagina and perineum |
US6136551A (en) * | 1995-04-24 | 2000-10-24 | Allergan, Inc. | Assay for detecting the presence of botulinum toxin neutralizing antibodies in a patient serum sample |
DK0773788T3 (da) | 1995-06-06 | 2003-09-01 | Allergan Inc | Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner |
US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
US6699966B1 (en) * | 1996-07-08 | 2004-03-02 | University Of Massachusetts | Proteins within the type E botulinum neurotoxin complex |
CN1057430C (zh) * | 1996-10-09 | 2000-10-18 | 崔生发 | 一种生物化学杀鼠剂 |
TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
EP1586329A1 (de) * | 2000-02-08 | 2005-10-19 | Allergan, Inc. | Pharmazeutische Zusammensetzungen mit botulinum Toxin |
US6358513B1 (en) | 2000-02-15 | 2002-03-19 | Allergan Sales, Inc. | Method for treating Hashimoto's thyroiditis |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
WO2006096164A1 (en) * | 2005-03-03 | 2006-09-14 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
US20080096238A1 (en) * | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
WO2006101809A1 (en) | 2005-03-15 | 2006-09-28 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
US7855268B2 (en) * | 2006-06-01 | 2010-12-21 | Allergan, Inc. | Tolerogizing compositions comprising botulinum toxin type B peptides |
-
1999
- 1999-08-31 TW TW88114941A patent/TW574036B/zh active
- 1999-09-07 SA SA99200566A patent/SA99200566B1/ar unknown
- 1999-09-09 RS YUP-190/01A patent/RS50344B/sr unknown
- 1999-09-09 WO PCT/US1999/020912 patent/WO2000015245A2/en active IP Right Grant
- 1999-09-09 SI SI9920081A patent/SI20566B/sl not_active IP Right Cessation
- 1999-09-09 IL IL14156499A patent/IL141564A0/xx unknown
- 1999-09-09 EP EP99945649A patent/EP1112082B2/de not_active Expired - Lifetime
- 1999-09-09 EA EA200100337A patent/EA003367B1/ru not_active IP Right Cessation
- 1999-09-09 GE GEAP19995844A patent/GEP20032946B/en unknown
- 1999-09-09 CN CNB998107395A patent/CN100438905C/zh not_active Expired - Fee Related
- 1999-09-09 DE DE69902396T patent/DE69902396T3/de not_active Expired - Lifetime
- 1999-09-09 PT PT99945649T patent/PT1112082E/pt unknown
- 1999-09-09 BR BR9913585-0A patent/BR9913585A/pt not_active Application Discontinuation
- 1999-09-09 CA CA2342243A patent/CA2342243C/en not_active Expired - Lifetime
- 1999-09-09 AU AU58214/99A patent/AU755556C/en not_active Ceased
- 1999-09-09 AR ARP990104540A patent/AR022671A1/es unknown
- 1999-09-09 HU HU0103638A patent/HUP0103638A3/hu unknown
- 1999-09-09 ID IDW20010592A patent/ID28824A/id unknown
- 1999-09-09 ES ES99945649T patent/ES2181473T5/es not_active Expired - Lifetime
- 1999-09-09 UA UA2001042366A patent/UA72477C2/uk unknown
- 1999-09-09 TR TR2001/00728T patent/TR200100728T2/xx unknown
- 1999-09-09 DK DK99945649.4T patent/DK1112082T4/da active
- 1999-09-09 EE EEP200100140A patent/EE200100140A/xx unknown
- 1999-09-09 CO CO99057166A patent/CO5170497A1/es not_active Application Discontinuation
- 1999-09-09 JP JP2000569829A patent/JP4557426B2/ja not_active Expired - Lifetime
- 1999-09-09 AP APAP/P/2001/002108A patent/AP1591A/en active
- 1999-09-09 AT AT99945649T patent/ATE221386T1/de active
- 1999-09-09 US US09/393,590 patent/US7211261B1/en not_active Expired - Lifetime
- 1999-09-09 SK SK313-2001A patent/SK286919B6/sk not_active IP Right Cessation
- 1999-09-09 KR KR1020017003032A patent/KR100699756B1/ko not_active IP Right Cessation
- 1999-09-09 PL PL347069A patent/PL200926B1/pl not_active IP Right Cessation
- 1999-09-09 SI SI9930126T patent/SI1112082T1/xx unknown
- 1999-09-09 NZ NZ509349A patent/NZ509349A/en not_active IP Right Cessation
-
2001
- 2001-01-31 IS IS5836A patent/IS2381B/is unknown
- 2001-02-21 IL IL141564A patent/IL141564A/en not_active IP Right Cessation
- 2001-02-28 ZA ZA200101709A patent/ZA200101709B/en unknown
- 2001-03-09 NO NO20011207A patent/NO328898B1/no not_active IP Right Cessation
- 2001-03-12 CU CU20010063A patent/CU23251A3/es not_active IP Right Cessation
- 2001-04-09 HR HR20010259A patent/HRP20010259B1/xx not_active IP Right Cessation
- 2001-04-10 BG BG105435A patent/BG65555B1/bg unknown
- 2001-04-10 LT LT2001041A patent/LT4959B/lt not_active IP Right Cessation
- 2001-04-10 LV LV010056A patent/LV12684B/xx unknown
-
2002
- 2002-04-10 HK HK02102724.7A patent/HK1040927A1/xx not_active IP Right Cessation
-
2007
- 2007-03-08 US US11/683,628 patent/US8173138B2/en not_active Expired - Fee Related
- 2007-03-27 JP JP2007083103A patent/JP2007169301A/ja not_active Withdrawn
-
2010
- 2010-02-26 JP JP2010043514A patent/JP5270594B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-28 JP JP2013039884A patent/JP2013144691A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69902396T2 (de) | Stabilisierte flüssige arzneizubereitungen enthaltend botulinum toxin | |
DE69831620D1 (de) | Arzneizubereitungen enthaltend Kannabinoide | |
DE122010000011I1 (de) | Flüssige gonadotropinhaltige Arzneimittel | |
IS5953A (is) | Lyfjablöndur úr örgerðum eplerenonum | |
DK0981375T3 (da) | Farmaceutiske præparater indeholdende plasmaprotein | |
NO20021401D0 (no) | Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser | |
DE69814091D1 (de) | Voriconazol-enthaltende pharmazeutische zubereitungen | |
ATE200027T1 (de) | Tetrahydrolipstatin enthaltende präparate | |
DK1035771T3 (da) | Tensidsystemer til flydende vandige præparater | |
ATE265852T1 (de) | Geschmackskaschierte flüssige arzneizubereitungen | |
DK0988861T3 (da) | Stabiliserede proteinpræparater | |
ATE332132T1 (de) | Verbesserte arzneizubereitungen enthaltend ritonavir | |
NO20015711D0 (no) | Farmasöytiske preparater inneholdende anti-Fas-antistoff | |
DK0925273T3 (da) | Farmaceutiske præparater indeholdende 4-oxo-butansyrer | |
DE69926012D1 (de) | Arzneizubereitungen | |
NO995838D0 (no) | Nye heteroetynylenforbindelser og farmasöytiske og kosmetiske preparater inneholdende de samme | |
DK1041966T3 (da) | Farmaceutiske præparater omfattende zafirlukast | |
EE04701B1 (et) | Kihisevad preparaadid | |
EE9800275A (et) | Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid | |
DE69906934D1 (de) | Arzneizubereitungen | |
DE69904021D1 (de) | Flüsige pharmazeusche zubereitung enthaltend zotepin | |
DK0859635T3 (da) | Stabiliserede farmaceutiske præparater indeholdende dobutamin | |
GB9502133D0 (en) | Pharmaceutical composition containing botulinum neurotoxin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: SOLSTICE NEUROSCIENCES, INC., SAN DIEGO, CALIF., U |
|
8366 | Restricted maintained after opposition proceedings | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: VOSSIUS & PARTNER, 81675 MUENCHEN |